XML 13 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 243 $ 642 $ 881 $ 2,469
General and administrative 1,093 1,472 5,674 4,864
Total operating expenses 1,336 2,114 6,555 7,333
Loss from operations (1,336) (1,931) (6,555) (7,150)
Other (expense) income:        
Other income 200 3,556
Change in fair value of forward purchase agreement asset (23)
Change in fair value of SEPA put rights asset 230 55
Change in fair value of embedded derivative liability (150) (773)
Loss on settlement of convertible notes (214) (358)
Interest income 6 2 30 3
Interest expense (193) (164) (1,104) (306)
Total other (expense) income, net (321) (162) (1,973) 3,253
Net loss $ (1,657) $ (2,093) $ (8,528) $ (3,897)
Net loss per share, basic (in Dollars per share) $ (0.63) $ (3.27) $ (4.12) $ (6.09)
Net loss per share, diluted (in Dollars per share) $ (0.63) $ (3.27) $ (4.12) $ (6.09)
Weighted averages shares outstanding        
Weighted average shares outstanding - basic (in Shares) 2,613,889 640,606 2,069,965 639,996
Weighted average shares outstanding - diluted (in Shares) 2,613,889 640,606 2,069,965 639,996
Research and development services        
Revenue:        
Revenue $ 183 $ 183